Christine M McMahon1, Selina M Luger2,3. 1. Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. 2. Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. selina.luger@uphs.upenn.edu. 3. Perelman Center for Advanced Medicine, 12th Floor South Extension, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. selina.luger@uphs.upenn.edu.
Abstract
PURPOSE OF REVIEW: Patients with relapsed T cell acute lymphoblastic leukemia (T-ALL) have limited therapeutic options and a poor prognosis. Although a variety of salvage chemotherapy regimens may be used, response rates are unsatisfactory. This article summarizes current approaches and promising emerging strategies for the treatment of relapsed T-ALL. RECENT FINDINGS: Although nelarabine is the only agent approved specifically for T-ALL, recent studies have identified a variety of genetic alterations and signaling pathways that are critical in its pathogenesis. Based on these findings, a number of small-molecule inhibitors and other targeted therapies are being studied for relapsed T-ALL, including gamma-secretase inhibitors, BCL-2 inhibitors, cyclin-dependent kinase inhibitors, and mTOR inhibitors. In addition, pre-clinical studies of chimeric antigen receptor T cells targeting CD5 and CD7 as well as the monoclonal antibody daratumumab have shown promising results for T-ALL. Relapsed T-ALL currently remains challenging to treat, but recent pre-clinical studies of targeted and immunotherapeutic agents have shown encouraging results. A number of clinical trials investigating these approaches for T-ALL are currently underway.
PURPOSE OF REVIEW: Patients with relapsed T cell acute lymphoblastic leukemia (T-ALL) have limited therapeutic options and a poor prognosis. Although a variety of salvage chemotherapy regimens may be used, response rates are unsatisfactory. This article summarizes current approaches and promising emerging strategies for the treatment of relapsed T-ALL. RECENT FINDINGS: Although nelarabine is the only agent approved specifically for T-ALL, recent studies have identified a variety of genetic alterations and signaling pathways that are critical in its pathogenesis. Based on these findings, a number of small-molecule inhibitors and other targeted therapies are being studied for relapsed T-ALL, including gamma-secretase inhibitors, BCL-2 inhibitors, cyclin-dependent kinase inhibitors, and mTOR inhibitors. In addition, pre-clinical studies of chimeric antigen receptor T cells targeting CD5 and CD7 as well as the monoclonal antibody daratumumab have shown promising results for T-ALL. Relapsed T-ALL currently remains challenging to treat, but recent pre-clinical studies of targeted and immunotherapeutic agents have shown encouraging results. A number of clinical trials investigating these approaches for T-ALL are currently underway.
Entities:
Keywords:
Refractory; Relapse; T cell acute lymphoblastic leukemia; T-ALL; Treatment
Authors: Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster Journal: Science Date: 2004-10-08 Impact factor: 47.728
Authors: Susan O'Brien; Gary Schiller; John Lister; Lloyd Damon; Stuart Goldberg; Walter Aulitzky; Dina Ben-Yehuda; Wendy Stock; Steven Coutre; Dan Douer; Leonard T Heffner; Melissa Larson; Karen Seiter; Scott Smith; Sarit Assouline; Philip Kuriakose; Lori Maness; Arnon Nagler; Jacob Rowe; Markus Schaich; Ofer Shpilberg; Karen Yee; Guenter Schmieder; Jeffrey A Silverman; Deborah Thomas; Steven R Deitcher; Hagop Kantarjian Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: Marta Sanchez-Martin; Alberto Ambesi-Impiombato; Yue Qin; Daniel Herranz; Mukesh Bansal; Tiziana Girardi; Elisabeth Paietta; Martin S Tallman; Jacob M Rowe; Kim De Keersmaecker; Andrea Califano; Adolfo A Ferrando Journal: Proc Natl Acad Sci U S A Date: 2017-02-07 Impact factor: 11.205
Authors: Barbara L Asselin; Meenakshi Devidas; Chenguang Wang; Jeanette Pullen; Michael J Borowitz; Robert Hutchison; Steven E Lipshultz; Bruce M Camitta Journal: Blood Date: 2011-04-07 Impact factor: 22.113
Authors: V Agnusdei; S Minuzzo; C Frasson; A Grassi; F Axelrod; S Satyal; A Gurney; T Hoey; E Seganfreddo; G Basso; S Valtorta; R M Moresco; A Amadori; S Indraccolo Journal: Leukemia Date: 2013-06-18 Impact factor: 11.528
Authors: Alejandro Gutierrez; Takaomi Sanda; Ruta Grebliunaite; Arkaitz Carracedo; Leonardo Salmena; Yebin Ahn; Suzanne Dahlberg; Donna Neuberg; Lisa A Moreau; Stuart S Winter; Richard Larson; Jianhua Zhang; Alexei Protopopov; Lynda Chin; Pier Paolo Pandolfi; Lewis B Silverman; Stephen P Hunger; Stephen E Sallan; A Thomas Look Journal: Blood Date: 2009-05-20 Impact factor: 22.113
Authors: Anja Möricke; Martin Zimmermann; Maria Grazia Valsecchi; Martin Stanulla; Andrea Biondi; Georg Mann; Franco Locatelli; Giovanni Cazzaniga; Felix Niggli; Maurizio Aricò; Claus R Bartram; Andishe Attarbaschi; Daniela Silvestri; Rita Beier; Giuseppe Basso; Richard Ratei; Andreas E Kulozik; Luca Lo Nigro; Bernhard Kremens; Jeanette Greiner; Rosanna Parasole; Jochen Harbott; Roberta Caruso; Arend von Stackelberg; Elena Barisone; Claudia Rössig; Valentino Conter; Martin Schrappe Journal: Blood Date: 2016-02-17 Impact factor: 22.113
Authors: Adele K Fielding; Susan M Richards; Rajesh Chopra; Hillard M Lazarus; Mark R Litzow; Georgina Buck; I Jill Durrant; Selina M Luger; David I Marks; Ian M Franklin; Andrew K McMillan; Martin S Tallman; Jacob M Rowe; Anthony H Goldstone Journal: Blood Date: 2006-10-10 Impact factor: 22.113
Authors: Yoshihiro Gocho; Jingjing Liu; Jianzhong Hu; Wentao Yang; Neekesh V Dharia; Jingliao Zhang; Hao Shi; Guoqing Du; August John; Ting-Nien Lin; Jeremy Hunt; Xin Huang; Bensheng Ju; Lauren Rowland; Lei Shi; Dylan Maxwell; Brandon Smart; Kristine R Crews; Wenjian Yang; Kohei Hagiwara; Yingchi Zhang; Kathryn Roberts; Hong Wang; Elias Jabbour; Wendy Stock; Bartholomew Eisfelder; Elisabeth Paietta; Scott Newman; Giovanni Roti; Mark Litzow; John Easton; Jinghui Zhang; Junmin Peng; Hongbo Chi; Stanley Pounds; Mary V Relling; Hiroto Inaba; Xiaofan Zhu; Steven Kornblau; Ching-Hon Pui; Marina Konopleva; David Teachey; Charles G Mullighan; Kimberly Stegmaier; William E Evans; Jiyang Yu; Jun J Yang Journal: Nat Cancer Date: 2021-01-21